Avandia Lawsuit Heart Attack Attorney
About Avandia
Avandia Under Fire Again
Category: About Avandia
In this week's issue of The Journal of the American Medical Association a pair of new articles add more fuel to the fire surrounding the type-2 diabetes medication Avandia. The articles also points the finger at Actos, a similar drug. The new studies allege that Avandia exponentially increases the chance of heart failure and heart attacks.
Avandia- Harmful to One's Health?
Category: About Avandia
On July 30, 2007, an FDA panel voted 22-1 in favor of keeping the diabetes drug, Avandia, on the market despite the fact that 42 different studies have shown that taking Avandia increases the risk of heart attacks by 43 percent.
Avandia Reminder
Category: About Avandia
Prescribers of rosiglitazone (marketed by Avandia) were reminded by the Ministry of Health
to not disregard the restrictions for use of the drug in patients with cardiovascular disease.
Avandia Warning
Category: About Avandia
The FDA has been criticizing the handling of Avandia for the past three weeks now. Avandia was the subject of a meta-analysis which is an overview of the results of many smaller studies. In the study, it was found that those taking Avandia had a 43% greater chance of death or heart attack than those not taking the drug.
Medicine is extending lives, but not for diabetic women
Category: About Avandia
Advances in medical care over the last three decades have reduced heart disease and extended lives, but not for women with diabetes.
Continue reading "Medicine is extending lives, but not for diabetic women"
Drug Company Threatened Doctor with Lawsuit Over Safety Concerns
Category: About Avandia
A medical expert disclosed to a House panel that the drug company that makes a widely used diabetes drug, had threatened him with a lawsuit after he raised safety concerns regarding Avandia.
Continue reading "Drug Company Threatened Doctor with Lawsuit Over Safety Concerns"
About Avandia (Rosiglitazone)
Category: About Avandia
Rosiglitazone, approved in 1999, is an anti-diabetic drug used to treat people with type 2 diabetes. Rosiglitazone is in the thiazolidinedione class and marketed under the brand name Avandia, by the pharmaceutical company GlaxoSmithKline.
Avandia works by helping to restore the body's proper response to insulin, thereby lowering blood sugar.